Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.The Journal of clinical investigation · 2026
   Article
2. Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy.Nature communications · 2025
   Article
3. Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer.Molecular cancer research : MCR · 2024
   Article
4. Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective.Frontiers in oncology · 2022
   Review
5. Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.Medicinal research reviews · 2019
   Review
6. Current treatment strategies for advanced prostate cancer.International journal of urology : official journal of the Japanese Urological Association · 2018
   Review
7. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.Molecular cancer therapeutics · 2017
   Article
8. Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer.Asian journal of andrology
   Review

Corrections and comments

• Erratum for
  Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.2014

Authors and funding

13 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.